Therapeutic Efficacy of Antibodies Lacking FcγR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Efficacy of Antibodies Lacking FcγR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
Authors
Keywords
Antibodies, Dengue virus, Virions, Cell fusion, Immune serum, West Nile virus, Enzyme-linked immunoassays, Stoichiometry
Journal
PLoS Pathogens
Volume 9, Issue 2, Pages e1003157
Publisher
Public Library of Science (PLoS)
Online
2013-02-15
DOI
10.1371/journal.ppat.1003157
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
- (2012) Arunee Sabchareon et al. LANCET
- Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
- (2012) R. de Alwis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of Dengue Virus Broad Cross-Neutralization by a Monoclonal Antibody
- (2012) Joseph J.B. Cockburn et al. STRUCTURE
- Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo
- (2012) Katherine L. Williams et al. VIROLOGY
- Analysis of Epitopes on Dengue Virus Envelope Protein Recognized by Monoclonal Antibodies and Polyclonal Human Sera by a High Throughput Assay
- (2012) Hong-En Lin et al. PLoS Neglected Tropical Diseases
- Immune Response to Dengue Virus and Prospects for a Vaccine
- (2011) Brian R. Murphy et al. Annual Review of Immunology
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
- (2011) Bruno Guy et al. VACCINE
- Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity
- (2011) Federico Narvaez et al. PLoS Neglected Tropical Diseases
- In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection
- (2011) Ruklanthi de Alwis et al. PLoS Neglected Tropical Diseases
- A Dynamic Landscape for Antibody Binding Modulates Antibody-Mediated Neutralization of West Nile Virus
- (2011) Kimberly A. Dowd et al. PLoS Pathogens
- Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease
- (2010) Raphaël M. Zellweger et al. Cell Host & Microbe
- The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
- (2010) Martina Beltramello et al. Cell Host & Microbe
- Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
- (2010) K. Matsui et al. JOURNAL OF GENERAL VIROLOGY
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults
- (2010) Dennis Morrison et al. JOURNAL OF INFECTIOUS DISEASES
- An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection
- (2010) C. M. Midgley et al. JOURNAL OF VIROLOGY
- Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2
- (2010) S. Sukupolvi-Petty et al. JOURNAL OF VIROLOGY
- Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City
- (2010) Jorge Poo et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354
- (2010) B. Kaufmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
- (2010) W. Dejnirattisai et al. SCIENCE
- Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape
- (2010) Gregory D. Gromowski et al. VIROLOGY
- Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification
- (2010) Scott J. Balsitis et al. PLoS Pathogens
- Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody
- (2009) Mickaël V Cherrier et al. EMBO JOURNAL
- Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens
- (2009) Wayne D. Crill et al. PLoS One
- Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody
- (2009) W.M.P.B. Wahala et al. VIROLOGY
- A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes
- (2009) Bruce S. Thompson et al. PLoS Pathogens
- Global Spread and Persistence of Dengue
- (2008) Jennifer L. Kyle et al. Annual Review of Microbiology
- Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus
- (2008) G. D. Gromowski et al. JOURNAL OF VIROLOGY
- Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II
- (2008) C.-Y. Lai et al. JOURNAL OF VIROLOGY
- Geographic Expansion of Dengue: The Impact of International Travel
- (2008) Annelies Wilder-Smith et al. MEDICAL CLINICS OF NORTH AMERICA
- Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins
- (2008) Shee-Mei Lok et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization
- (2008) Steevenson Nelson et al. PLoS Pathogens
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started